4/18
03:45 pm
itci
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success [Yahoo! Finance]
Low
Report
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success [Yahoo! Finance]
4/18
02:50 am
itci
Intra-Cellular Therapies drops 2%, prices $500M equity financing [Seeking Alpha]
Medium
Report
Intra-Cellular Therapies drops 2%, prices $500M equity financing [Seeking Alpha]
4/17
08:46 pm
itci
Intra-Cellular Therapies Prices Public Offering of Common Stock
Medium
Report
Intra-Cellular Therapies Prices Public Offering of Common Stock
4/17
03:26 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at TD Cowen from $80.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at TD Cowen from $80.00 to $90.00. They now have a "buy" rating on the stock.
4/17
03:26 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Robert W. Baird from $83.00 to $103.00. They now have an "outperform" rating on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Robert W. Baird from $83.00 to $103.00. They now have an "outperform" rating on the stock.
4/17
03:26 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Bank of America Co. from $82.00 to $91.00. They now have a "buy" rating on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its price target raised by analysts at Bank of America Co. from $82.00 to $91.00. They now have a "buy" rating on the stock.
4/17
11:40 am
itci
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals [Yahoo! Finance]
Medium
Report
Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals [Yahoo! Finance]
4/17
09:33 am
itci
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last? [Yahoo! Finance]
Low
Report
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last? [Yahoo! Finance]
4/16
04:06 pm
itci
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Low
Report
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
4/16
01:33 pm
itci
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data [Seeking Alpha]
Low
Report
Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data [Seeking Alpha]
4/16
08:00 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.
4/16
07:19 am
itci
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder [Yahoo! Finance]
High
Report
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder [Yahoo! Finance]
4/16
07:00 am
itci
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
High
Report
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
4/5
08:03 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $82.00 price target on the stock.
4/3
09:31 am
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
3/24
10:45 am
itci
Intra-Cellular Therapies (NASDAQ:ITCI) advances 6.5% this week, taking five-year gains to 467% [Yahoo! Finance]
Low
Report
Intra-Cellular Therapies (NASDAQ:ITCI) advances 6.5% this week, taking five-year gains to 467% [Yahoo! Finance]
3/19
08:47 am
itci
Intra-Cellular Therapies promotes Michael Halstead to President [Seeking Alpha]
Low
Report
Intra-Cellular Therapies promotes Michael Halstead to President [Seeking Alpha]
3/19
08:33 am
itci
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes [Yahoo! Finance]
Low
Report
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes [Yahoo! Finance]
3/19
08:30 am
itci
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
Low
Report
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
3/11
07:17 pm
itci
Intra-Cellular Therapies Is On Fire [Seeking Alpha]
Low
Report
Intra-Cellular Therapies Is On Fire [Seeking Alpha]
3/6
08:00 am
itci
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Low
Report
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
2/27
08:04 am
itci
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference [Yahoo! Finance]
Low
Report
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference [Yahoo! Finance]
2/27
08:00 am
itci
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
Low
Report
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
2/23
12:15 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $86.00 price target on the stock.
2/23
12:15 pm
itci
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $101.00 price target on the stock.
Low
Report
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $101.00 price target on the stock.